The sequencing of novel therapies in myeloma (CAR-T, bispecifics, antibody-drug conjugates)

Niels Van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, comments on the rapidly evolving landscape of multiple myeloma (MM) treatment, discussing the current evidence for the optimal sequencing of novel therapeutic options, such as CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.